REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Jun. 21, 2022-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in June.

Details of the events are as follows:

Truist Securities Cell Therapy Symposium, Symposia-cel, June 28, 2022

• Chen Schor, President & CEO, will participate in a panel discussion titled, “The Next Cells & Mechanisms to Watch in Oncology” on Tuesday, June 28, 2022, at 11:30 A.M. ET.

Stifel 2022 Virtual Cell Therapy Summit, June 29-30, 2022

• Chen Schor, President & CEO, will participate in a panel discussion titled, “Outlining the Potential of New Cell Types and Novel Approaches” on Wednesday, June 29, 2022, at 1:00 P.M. ET.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005986/en/

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.